Focused On-demand Library for DNA-directed RNA polymerases I, II, and III subunit RPABC2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P61218

UPID:

RPAB2_HUMAN

Alternative names:

DNA-directed RNA polymerase II subunit F; DNA-directed RNA polymerases I, II, and III 14.4 kDa polypeptide; RPABC14.4; RPB6 homolog; RPC15

Alternative UPACC:

P61218; P41584; Q6IAY3

Background:

DNA-directed RNA polymerases I, II, and III subunit RPABC2, also known as DNA-directed RNA polymerase II subunit F, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates. It is a crucial component of RNA polymerases I, II, and III, which are responsible for synthesizing ribosomal RNA precursors, mRNA precursors, functional non-coding RNAs, and small RNAs such as 5S rRNA and tRNAs. The protein is part of the clamp element in Pol II, contributing to the formation of a pocket essential for binding the RPB4-RPB7 subcomplex.

Therapeutic significance:

Understanding the role of DNA-directed RNA polymerases I, II, and III subunit RPABC2 could open doors to potential therapeutic strategies.